检验医学 ›› 2016, Vol. 31 ›› Issue (3): 212-216.DOI: 10.3969/j.issn.1673-8640.2016.03.014

• 技术研究与评价·论著 • 上一篇    下一篇

S100B蛋白在血脑屏障损伤评估中的应用价值

潘之光1, 秦嘉倩2, 吴炯2, 宋斌斌2, 郭玮2   

  1. 1. 复旦大学附属华山医院神经外科,上海 200040
    2. 复旦大学附属中山医院检验科,上海 200032
  • 收稿日期:2015-10-27 出版日期:2016-03-30 发布日期:2016-04-08
  • 作者简介:null

    作者简介:潘之光,男,1984年生,主要从事胶质瘤临床治疗研究。

    通讯作者:郭 玮,联系电话:021-64041990-2376。

  • 基金资助:
    “十二五”国家科技支撑计划资助项目(2012BAI37B01);国家临床重点检验专科建设资助项目;上海申康医院发展中心资助项目(SHDC22014017)

Application significance of S100B in the assessment of blood-brain barrier injury

PAN Zhiguang1, QIN Jiaqian2, WU Jiong2, SONG Binbin2, GUO Wei2   

  1. 1.Department of Neurosurgery,Huashan Hospital,Fudan University,Shanghai 200040,China
    2. Department of Clinical Laboratory,Zhongshan Hospital,Fudan University,Shanghai 200032,China
  • Received:2015-10-27 Online:2016-03-30 Published:2016-04-08

摘要:

目的系统评估电化学发光法测定血清S100B蛋白的性能,并初步探讨血清S100B蛋白水平与血脑屏障破坏程度的关联。方法参考美国临床实验室标准化协会(CLSI)EP-15A文件对S100B蛋白的精密度进行验证,同时验证该方法的线性和正确度。检测45例血脑屏障受损患者血清S100B蛋白浓度。根据脑脊液蛋白电泳试验中白蛋白商值(QALB)检测结果的四分位数[<第25百分位数(P25)、P25~<第50百分位数(P50)、P50~<第75百分位数(P75)、≥P75]对患者进行分组[<P25组(低QALB组)11例、P25~<P50组(中QALB组)11例、P50~<P75组(高QALB组)11例、≥P75组(极高QALB组)12例],观察S100B蛋白与血脑屏障破坏程度两者之间的关系。结果3个水平(S1浓度为0.05 µg/L、S2为0.12 µg/L、S3为2.75 µg/L)混合血清的批内变异系数(CV)分别为5.08%、3.00%和5.23%,批间CV分别为5.07%、3.27%和5.46%;2个水平校准品的验证值与靶值的相对偏移分别为5.26%和0.41%;检测线性范围为0.01~36.00 μg/L,线性良好(Y=0.999X+0.003,R2=0.999)。低QALB组S100B蛋白水平明显低于极高QALB组(P=0.04),其余各组间差异无统计学意义(P>0.05)。结论电化学发光法测定S100B蛋白的检测性能符合临床要求,可在临床上推广应用。血清S100B蛋白浓度可反映血脑屏障破坏程度,有助于临床评估病情。

关键词: S100B蛋白, 血脑屏障, 性能评价

Abstract:

Objective To evaluate the performance of serum S100B determination kit based on electro-chemiluminescence immunoassay,and to investigate preliminarily the correlation between serum S100B concentration and the severity of blood-brain barrier injury. Methods The precision was validated according to the Clinical and Laboratory Standards Institute (CLSI) EP-15A protocols. Linearity and accuracy were also validated. A total of 45 patients with blood-brain barrier injury were enrolled. Serum S100B concentrations were determined. The patients were classified into 4 groups according to quotient albumin(QALB)results [<the first quartile(P25),P25-<the second quartile(P50),P50-<the third quartile(P75) and ≥P75] ,<P25(low QALB group,11 cases),P25-<P50 (middle QALB group,11 cases),P50-<P75 (high QALB group,11 cases) and ≥P75(extremely high QALB group,12 cases). The correlation between S100B and the severity of blood-brain barrier injury was observed. Results The within-run coefficients of variations(CV) of 3 concentrations (S1 = 0.05 µg/L,S2 = 0.12 µg/L and S3 = 2.75 µg/L)were 5.08%,3.00% and 5.23%,and the between-run CV were 5.07%,3.27% and 5.46%, respectively. Relative biases were 5.26% and 0.41%,respectively. The linear range was 0.01-36.00μg/L, which indicating a satisfied linearity (Y = 0.999X + 0.003,R2= 0.999). The S100B concentration in low QALB group was significantly lower than that in extremely high QALB group (P = 0.04),and there was no statistical significance between the other 2 groups(P > 0.05). Conclusions Serum S100B determination kit based on electro-chemiluminescence immunoassay exhibits satisfied clinical performance,which is suitable for current clinical application. Serum S100B concentration could reflect the severity of blood-brain barrier injury,and assist clinicians to evaluate the disease status for patients.

Key words: S100B, Blood-brain barrier, Performance assessment

中图分类号: